

October 25, 2018



# Syros to Report Third Quarter 2018 Financial Results on Thursday, November 1, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial results and provide a corporate update.

To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 3988733. A webcast of the call will also be available on the Investors & Media section of the Syros website at [www.syros.com](http://www.syros.com). An archived replay of the webcast will be available for approximately 30 days following the presentation.

## About Syros Pharmaceuticals

Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RAR $\alpha$  agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and breast cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20181025005060/en/>

## Media Contact:

Syros Pharmaceuticals  
Naomi Aoki, 617-283-4298  
[naoki@syros.com](mailto:naoki@syros.com)

or

## Investor Contact:

Stern Investor Relations, Inc.  
Hannah Deresiewicz, 212-362-1200  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

Source: Syros Pharmaceuticals